Unknown PHASE2 INTERVENTIONAL NCT00323583

Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer

Phase II Study of Paclitaxel, Oxaliplatin, Leucovorin and 5-Fluorouracil (POLF) in Gemcitabine-Refractory Advanced Pancreatic Cancer

Sponsor: Seattle Cancer Treatment and Wellness Center

Conditions Adenocarincoma of Pancreas Stage III Pancreatic Cancer Stage IVA Pancreatic Cancer Stage IVB Pancreatic Cancer

Interventions 5-fluorouracil Chemoprotection Chemotherapy Complementary and alternative therapy calcium and magnesium glutathione leucovorin oxaliplatin paclitaxel

Updated 5 times since 2017 Last updated: May 7, 2007 Started: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Adenocarincoma of Pancreas and Stage III Pancreatic Cancer and is currently ongoing. Seattle Cancer Treatment and Wellness Center leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Seattle Cancer Treatment and Wellness Center

Data source: Seattle Cancer Treatment and Wellness Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States